var data={"title":"Cholestyramine resin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cholestyramine resin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5892?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cholestyramine-resin-drug-information\" class=\"drug drug_general\">see &quot;Cholestyramine resin: Drug information&quot;</a> and <a href=\"topic.htm?path=cholestyramine-resin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cholestyramine resin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150870\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Prevalite;</li>\n      <li>Questran;</li>\n      <li>Questran Light</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150871\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Novo-Cholamine;</li>\n      <li>Novo-Cholamine Light;</li>\n      <li>Olestyr;</li>\n      <li>PMS-Cholestyramine;</li>\n      <li>Questran;</li>\n      <li>Questran Light Sugar Free;</li>\n      <li>ZYM-Cholestyramine-Light;</li>\n      <li>ZYM-Cholestyramine-Regular</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051702\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antilipemic Agent, Bile Acid Sequestrant</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20234285\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Diaper dermatitis:</b> Limited data available: Topical: Apply to affected area with each diaper change; <b>Note:</b> Product not commercially available; may be prepared as an extemporaneously compounded ointment or paste in Aquaphor; usual concentration: 5% to 10%; although higher concentrations (up to 20%) have been compounded; some centers have also used petrolatum as the base for compounding (White 2003; Williams 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051696\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=cholestyramine-resin-drug-information\" class=\"drug drug_general\">see &quot;Cholestyramine resin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diaper dermatitis:</b> Limited data available: Topical: Infants and Children: Apply to affected area with each diaper change; <b>Note:</b> Product not commercially available; may be prepared as an extemporaneously compounded ointment or paste in Aquaphor&reg; or polyethylene glycol; usual concentration 5% to 10%; although higher concentrations (up to 20%) have been compounded; some centers have also used petrolatum as the base for compounding (Preckshot 2001; White 2003; Williams 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dyslipidemia:</b> Limited data available: Oral: <b>Note:</b> Dosages are expressed in terms of anhydrous resin: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Age-directed (fixed-dosing): Children &ge;6 years and Adolescents: Initial 2 to 4 g/day for 1 week, then increase as tolerated to 8 g/day; children &lt;10 years of age may only tolerate daily dose of 4 g (McCrindle 2007; Sprecher 1996; Tonstad 1996); lipid-lowering effects are better if dose is administered as a single daily dose with the evening meal (single daily morning doses are less effective); if patients cannot tolerate once daily dosing, the total daily dose may be divided into 2 doses and administered with the morning and evening meals; may also be administered in 3 divided doses daily (Daniels 2002); doses &gt;8 g/day may not provide additional significant cholesterol-lowering effects, but may increase adverse effects (Sprecher 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-directed dosing: Children and Adolescents: 240 mg/kg/day in 3 divided doses; titrate to effect, maximum daily dose: 8 g/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pruritus secondary to cholestasis:</b> Limited data available: Oral: <b>Note:</b> Dosages are expressed in terms of anhydrous resin:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &le;10 years: 240 mg/kg/day in 2 or 3 divided doses administered in the morning around breakfast and if necessary, the third dose at lunch; may titrate dose to effect. Some experts have suggested a maximum daily dose of 4 g/day; however, higher doses have been reported to treat pruritus in pediatric patients &lt;10 years; in a case report (age: 9 years), the reported effective dose range was 3.3 to 6.6 g/day; in another case series (n=3; ages: 3-9 years), the reported range was 1.7 to 10 g/day; in some patients, higher doses were associated with increased steatorrhea and required dosage reduction (Cies 2007; Sprecher 1996) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;10 years and Adolescents: 240 mg/kg/day administered in the morning before breakfast; may titrate dose to effect. Some experts have suggested a maximum daily dose of 8 g/day; in adult patients, the AASLD guidelines recommend an initial dose of 4 g/day; may titrate up to 16 g/day; in some patients, higher doses have been associated with increased steatorrhea requiring dose reduction (Cies 2007; Iman 2012; Lindor 2009; Sprecher 1996).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diarrhea secondary to intestinal failure, short-bowel syndrome:</b> Limited data available: Children and Adolescents: Oral: 240 mg/kg/day in 3 divided doses; maximum daily dose: 8 g/day has been suggested (Ching 2009); however, trials have not been completed in pediatric patients and others have recommended avoiding use at this time  (ASPEN Core Curriculum 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Dosages are expressed in terms of anhydrous resin: <b>Dyslipidemia:</b> Oral: Initial: 4 g 1 to 2 times daily; increase gradually over &ge;1-month intervals; maintenance: 8-16 g/day divided in 2 doses; maximum: 24 g/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustment provided in manufacturer's labeling; however, use with caution in renal impairment; may cause hyperchloremic acidosis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> No dosage adjustment necessary; not absorbed from the gastrointestinal tract.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150849\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Packet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prevalite: 4 g (1 ea, 42 ea, 60 ea) [contains aspartame; orange flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Questran: 4 g (1 ea, 60 ea) [orange flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 g (1 ea, 60 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Powder, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prevalite: 4 g/dose (231 g) [contains aspartame; orange flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Questran: 4 g/dose (378 g) [orange flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Questran Light: 4 g/dose (210 g) [sugar free; contains aspartame; orange flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 g/dose (210 g, 231 g, 239.4 g, 378 g)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150834\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051705\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer as prepared suspension; not to be taken in dry form orally; suspension should not be sipped or held in mouth for prolonged periods (may cause tooth discoloration or enamel decay). Administration at mealtime is recommended. Administer other drugs including vitamins or mineral supplements at least 1 hour before or at least 4 to 6 hours after cholestyramine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dyslipidemia: Administer as a single dose (preferably) with the evening meal; however, some patients may require divided doses; in pediatric patients, may use 2 to 3 divided doses and in adults up to 6 doses daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pruritus; cholestasis: Administer before breakfast (gall bladder has highest concentration of bile acids available for binding); for patients with an intact gall bladder, it has been suggested to administer the first dose 30 minutes before breakfast, the second dose 30 minutes after breakfast, and the final dose with lunch (Cies 2007)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150865\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051704\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Adjunct in the management of primary hypercholesterolemia (FDA approved in adults); pruritus associated with elevated levels of bile acids (FDA approved in adults); has also been used to manage diarrhea associated with excess fecal bile acids; applied topically to treat diaper dermatitis and as a skin-protectant around enterostomy fistula sites. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150895\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Edema, syncope</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Anxiety, dizziness, drowsiness, fatigue, headache, neuralgia, paresthesia, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Perianal skin irritation, skin irritation, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Hyperchloremic metabolic acidosis (children), increased libido, weight gain, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, anorexia, biliary colic, constipation, dental bleeding, dental caries, dental discoloration, diarrhea, diverticulitis, duodenal ulcer with hemorrhage, dysgeusia, dysphagia, eructation, flatulence, gallbladder calcification, gastric ulcer, gastrointestinal hemorrhage, hemorrhoidal bleeding, hiccups, intestinal obstruction (rare), melena, nausea, pancreatitis, rectal pain, steatorrhea, tongue irritation, tooth enamel damage (dental erosion), vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Diuresis, dysuria, hematuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Adenopathy, anemia, bruise, hemorrhage, hypoprothrombinemia, prolonged prothrombin time, rectal hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Abnormal hepatic function tests</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, arthritis, back pain, myalgia, osteoporosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Nocturnal amblyopia (rare), uveitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Asthma, dyspnea, wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150856\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to bile acid sequestering resins or any component of the formulation; complete biliary obstruction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150838\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding: Chronic use may be associated with bleeding problems (especially in high doses); may be prevented with use of oral vitamin K therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Constipation: May produce or exacerbate constipation problems; initiate therapy at a reduced dose in patients with a history of constipation. Hemorrhoids may be worsened.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertriglyceridemia: Bile acid sequestrants should not be used in patients with baseline fasting triglyceride levels &ge;300 mg/dL or type III hyperlipoproteinemia since severe triglyceride elevations may occur. Use bile acid sequestrants with caution in patients with triglyceride levels 250 to 299 mg/dL and evaluate a fasting lipid panel in 4 to 6 weeks after initiation; discontinue use if triglycerides are &gt;400 mg/dL (Stone 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Decreased absorption (orally administered drugs): Not to be taken simultaneously with many other medicines (decreased absorption).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients susceptible to fat-soluble vitamin deficiencies: Use with caution in patients susceptible to fat-soluble vitamin deficiencies. Absorption of fat soluble vitamins A, D, E, and K and folic acid may be decreased; patients should take vitamins &ge;4 hours before cholestyramine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phenylalanine: Some products may contain phenylalanine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperlipidemia: Secondary causes of hyperlipidemia should be ruled out prior to therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25855404\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">With prolonged use, may potentially cause hypochloremic acidosis due to the exchange of organic anions for chloride; risk may be higher in younger and smaller patients; growth failure and malnutrition may occur in these patients (ASPEN Core Curriculum, 2010). Prolonged exposure to tooth enamel may result in discoloration or erosion; patients should be instructed to avoid sipping or slowly swallowing cholestyramine doses and to maintain good dental hygiene practices. May increase serum triglyceride concentrations; in a trial of children and adolescents (&gt;10 years of age); the serum triglycerides increased 6% to 9% from baseline (not statistically significant) (McCrindle, 1997). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299034\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150843\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13152&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acetaminophen: Cholestyramine Resin may decrease the absorption of Acetaminophen. Effect is minimal if cholestyramine is administered 1 hour after acetaminophen. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: Bile Acid Sequestrants may decrease the bioavailability of Amiodarone. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtorvaSTATin: Bile Acid Sequestrants may decrease the serum concentration of AtorvaSTATin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Bile Acid Sequestrants may decrease the absorption of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chenodiol: Bile Acid Sequestrants may decrease the serum concentration of Chenodiol.  Management: Administration of chenodiol 5 hours or more after bile acid sequestrants may reduce chenodiol adsorption in the gastrointestinal tract.  Monitor for decreased therapeutic effects of chenodiol in patients receiving bile acid sequestrants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholic Acid: Bile Acid Sequestrants may decrease the absorption of Cholic Acid.  Management: Administer cholic acid at least 1 to 4 hours before or 4 to 6 hours after administration of any bile acid-binding products to minimize the potential for a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Oral): Bile Acid Sequestrants may decrease the absorption of Corticosteroids (Oral). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Bile Acid Sequestrants may decrease the serum concentration of Deferasirox.  Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): Bile Acid Sequestrants may decrease the serum concentration of Estrogen Derivatives (Contraceptive).  Management: Administer estrogen-based oral contraceptives at least 1 to 4 hours prior to or 4 to 6 hours after administration of a bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ezetimibe: Bile Acid Sequestrants may decrease the absorption of Ezetimibe.  Management: Administer ezetimibe at least 2 hours before or 4 hours after any bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fibric Acid Derivatives: Bile Acid Sequestrants may decrease the absorption of Fibric Acid Derivatives.  Management: Separate doses by at least 2 hours to minimize this interaction; fenofibric acid labeling recommends administration one hour prior to or 4-6 hours after a bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluvastatin: Cholestyramine Resin may decrease the serum concentration of Fluvastatin.  Management: Administer fluvastatin at least 1 hour or greater (particularly with extended-release form) before, or at least 4 hours after cholestyramine to minimize the risk for any significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Bile Acid Sequestrants may decrease serum concentrations of the active metabolite(s) of Leflunomide.  Management: Unless using this combination to intentionally enhance leflunomide elimination, consider an alternative to the bile acid sequestrants when possible.  Separating drug administration is not likely to be effective at avoiding this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: Bile Acid Sequestrants may decrease the absorption of Lomitapide.  Management: Administer lomitapide at least 4 hours before or after administration of a bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Bile Acid Sequestrants may decrease the absorption of Loop Diuretics. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Bile Acid Sequestrants may decrease the absorption of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylfolate: Cholestyramine Resin may decrease the serum concentration of Methylfolate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): Bile Acid Sequestrants may decrease the serum concentration of Multivitamins/Fluoride (with ADE).  Management: Avoid concomitant administration of multivitamins and bile acid sequestrants (eg, cholestyramine). Separate administration of these agents by several hours to minimize the risk of an interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): Bile Acid Sequestrants may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, bile acid sequestrants may impair the absorption of fat-soluble vitamins.  Management: Avoid concomitant administration of multivitamins and bile acid sequestrants (eg, cholestyramine). Separate administration of these agents by several hours to minimize the risk of an interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): Bile Acid Sequestrants may decrease the serum concentration of Multivitamins/Minerals (with AE, No Iron).  Management: Avoid concomitant administration of multivitamins and bile acid sequestrants (e.g., cholestyramine). Separate administration of these agents by several hours to minimize the risk of an interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Cholestyramine Resin may decrease the serum concentration of Mycophenolate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Niacin: Bile Acid Sequestrants may decrease the absorption of Niacin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: Bile Acid Sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obeticholic Acid: Bile Acid Sequestrants may decrease the serum concentration of Obeticholic Acid.  Management: Administer obeticholic acid at least 4 hours before or at least 4 hours after the administration of bile acid sequestrants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: Cholestyramine Resin may decrease the serum concentration of PHENobarbital.  Management: Administer phenobarbital at least 1 hour before or 4-6 hours after administration of cholestyramine in order to minimize the risk for any significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pravastatin: Bile Acid Sequestrants may decrease the serum concentration of Pravastatin.  Management: Administer pravastatin at least 1 hour before or 4 hours after administration of bile-acid resins (eg, cholestyramine, colestipol, colesevelam) to minimize the risk for any significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): Bile Acid Sequestrants may decrease the serum concentration of Progestins (Contraceptive).  Management: Administer oral progestin-containing contraceptives at least 1 to 4 hours prior to or 4 to 6 hours after administration of a bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propranolol: Bile Acid Sequestrants may decrease the serum concentration of Propranolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raloxifene: Bile Acid Sequestrants may decrease the absorption of Raloxifene. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rosiglitazone: Cholestyramine Resin may decrease the serum concentration of Rosiglitazone.  Management: Administer rosiglitazone at least 2 hours prior to cholestyramine in order to minimize the likelihood of an interaction, and monitor patients closely for evidence of reduced rosiglitazone effectiveness.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Spironolactone: Cholestyramine Resin may enhance the adverse/toxic effect of Spironolactone. Specifically, the risks of developing metabolic acidosis and hyperkalemia may be elevated with this combination. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: Bile Acid Sequestrants may decrease the serum concentration of Teriflunomide.  Management: Unless using this combination to intentionally enhance teriflunomide elimination, consider an alternative to the bile acid sequestrants when possible.  Separating drug administration is unlikely to be effective at avoiding the interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: Bile Acid Sequestrants may decrease the absorption of Tetracyclines. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Bile Acid Sequestrants may decrease the absorption of Thiazide and Thiazide-Like Diuretics. The diuretic response is likewise decreased. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid Products: Bile Acid Sequestrants may decrease the serum concentration of Thyroid Products.  Management: Administer oral thyroid products at least 4 h prior to colesevelam, and at least 1 h before or 4-6 h after cholestyramine.  Specific recommendations for colestipol are not available. Monitor for decreased concentrations/effects of the thyroid product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ursodiol: Bile Acid Sequestrants may decrease the serum concentration of Ursodiol.  Management: Administer ursodiol 5 hours or more after bile acid sequestrants to minimize ursodiol adsorption in the gastrointestinal tract. Monitor for decreased therapeutic effects of ursodiol in patients receiving bile acid sequestrants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproic Acid and Derivatives: Cholestyramine Resin may decrease the serum concentration of Valproic Acid and Derivatives.  Management: Separate administration of valproic acid and cholestyramine by at least 3 hours whenever possible in order to minimize the potential for a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vancomycin: Bile Acid Sequestrants may diminish the therapeutic effect of Vancomycin.  Management: Avoid concurrent administration of oral vancomycin and bile acid sequestrants when possible.  If use of both agents is necessary, consider separating doses by at least 2 hours to minimize the significance of the interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D Analogs: Bile Acid Sequestrants may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs.  Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (eg, cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.<b> Exceptions: </b>Calcipotriene; Calcitriol (Topical); Tacalcitol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Bile Acid Sequestrants may decrease the absorption of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150866\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Cholestyramine (especially high doses or long-term therapy) may decrease the absorption of folic acid, calcium, fat-soluble vitamins (vitamins A, D, E, and K), and iron. Management: Supplementation of folic acid, calcium, fat-soluble vitamins (vitamins A, D, E, and K), and iron may be necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150846\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150859\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipid concentrations increase during pregnancy as required for normal fetal development. When increases are greater than expected, supervised dietary intervention should be initiated. Bile acid sequestrants are recommended when treatment is needed (Avis 2009; Jacobson 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholestyramine is not absorbed systemically, but may interfere with maternal vitamin absorption; therefore, regular prenatal supplementation may not be adequate.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051701\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric patients: Fasting lipid profile (baseline, 4 to 6 weeks after initiation, and then every 6 to 12 months), growth, maturation, number of stools per day (NHLBI, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults: Fasting lipid profile before initiating treatment, 3 months after initiation (within 4 to 6 weeks if baseline fasting triglycerides of 250 to 299 mg/dL), and every 6 to 12 months thereafter (Stone, 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150837\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Forms a nonabsorbable complex with bile acids in the intestine, releasing chloride ions in the process; inhibits enterohepatic reuptake of intestinal bile salts and thereby increases the fecal loss of bile salt-bound low density lipoprotein cholesterol</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150855\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Peak effect: 21 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: None </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (as insoluble complex with bile acids)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150858\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Cholestyramine Light Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g (60): $201.06</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Cholestyramine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g (60): $202.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Prevalite Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g (42): $214.51</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Questran Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g (1): $7.11</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Powder</b> (Cholestyramine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g/dose (378 g): $131.13</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Powder</b> (Prevalite Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g/dose (231 g): $137.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Powder</b> (Questran Light Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g/dose (210 g): $187.85</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Powder</b> (Questran Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g/dose (378 g): $186.79</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F150861\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Choles (TW);</li>\n      <li>Colestiramina (CL, CO, PY);</li>\n      <li>Colestrol (IT);</li>\n      <li>Efensol (ES);</li>\n      <li>Kolestran (TR);</li>\n      <li>Lipocol-Merz (DE);</li>\n      <li>Lipramina (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Olipo (BD);</li>\n      <li>Quantalan (CH, PT);</li>\n      <li>Quantalan Zuckerfrei (AT);</li>\n      <li>Questran (AE, BB, BE, BG, DK, EC, EG, FI, FR, GB, GR, HK, HN, IE, IS, IT, KR, KW, LU, MX, NL, NO, NZ, QA, SA, SE, SI, TH, VN);</li>\n      <li>Questran Light (AR, BB, BR, CZ, MY);</li>\n      <li>Questran Lite (AU, NZ, PH, ZA);</li>\n      <li>Questran Loc (DK, SE);</li>\n      <li>Resincolestiramina (ES, SG, TH, UY);</li>\n      <li>Semide (TW);</li>\n      <li>Sequest (ID);</li>\n      <li>Vasosan (PL);</li>\n      <li>Vasosan P-Granulat (DE);</li>\n      <li>Vasosan S-Granulat (DE, FR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Btaiche IF and Khalidi N, &quot;Parenteral Nutrition-Associated Liver Complications in Children,&quot; <i>Pharmacotherapy</i>, 2002, 22(2):188-211.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cholestyramine-resin-pediatric-drug-information/abstract-text/11837558/pubmed\" target=\"_blank\" id=\"11837558\">11837558</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carney LN, Nepa A, Cohen SS, et al, &ldquo;Parenteral and Enteral Nutrition Support: Determining the Best Way to Feed,&rdquo; In: Corkins MR, Balint J, Bobo E, et al, eds, <i>The A.S.P.E.N Pediatric Nutrition Support Core Curriculum</i>, Silver Spring: MD: American Society of Parenteral and Enteral Nutrition, 2010, 433-47.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ching YA, Gura K, and Modi B, &quot;Pediatric Intestinal Failure: Nutrition, Pharmacologic, and Surgical Approaches,&quot; <i>Nutr Clin Pract</i>, 2007, 22(6):653-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cholestyramine-resin-pediatric-drug-information/abstract-text/18042954/pubmed\" target=\"_blank\" id=\"18042954\">18042954</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cies JJ and Giamalis JN, &quot;Treatment of Cholestatic Pruritus in Children,&quot; <i>Am J Health Syst Pharm</i>, 2007, 64(11):1157-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cholestyramine-resin-pediatric-drug-information/abstract-text/17519457/pubmed\" target=\"_blank\" id=\"17519457\">17519457</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daniels SR, personal communication, May 2002.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Imam MH, Gossard AA, and Sinakos E, &quot;Pathogenesis and Management of Pruritus in Cholestatic Liver Disease,&quot; <i>J Gastroenterol Hepatol</i>, 2012, 27(7):1150-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cholestyramine-resin-pediatric-drug-information/abstract-text/22413872/pubmed\" target=\"_blank\" id=\"22413872\">22413872</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lindor KD, Gershwin ME, Poupon R, et al, &quot;Primary Biliary Cirrhosis,&quot; <i>Hepatology</i>, 2009, 50(1):291-308.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cholestyramine-resin-pediatric-drug-information/abstract-text/19554543/pubmed\" target=\"_blank\" id=\"19554543\">19554543</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCrindle BW, O'Neill MB, Cullen-Dean G, et al, &ldquo;Acceptability and Compliance With Two Forms of Cholestyramine in the Treatment of Hypercholesterolemia in Children: A Randomized, Crossover Trial,&rdquo; <i>J Pediatr</i>, 1997, 130(2):266-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cholestyramine-resin-pediatric-drug-information/abstract-text/9042130/pubmed\" target=\"_blank\" id=\"9042130\">9042130</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCrindle BW, Urbina EM, Dennison BA, et al, &quot;Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, With the Council on Cardiovascular Nursing,&quot; <i>Circulation</i>, 2007, 115(14):1948-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cholestyramine-resin-pediatric-drug-information/abstract-text/17377073/pubmed\" target=\"_blank\" id=\"17377073\">17377073</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Heart, Lung, and Blood Institute. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Clinical Practice Guidelines, 2011, National Institutes of Health. Available at <a href=\"http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf%20\" target=\"_blank\">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf </a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Preckshot J, et al, &quot;Cholestyramine 6.5% Ointment,&quot; <i>Int J Pharm Compound</i>, 2001, 5(1)42.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sprecher DL and Daniels SR, &ldquo;Rational Approach to Pharmacologic Reduction of Cholesterol Levels in Children,&rdquo; <i>J Pediatr</i>, 1996, 129(1):4-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cholestyramine-resin-pediatric-drug-information/abstract-text/8757557/pubmed\" target=\"_blank\" id=\"8757557\">8757557</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stone NJ, Robinson J, Lichtenstein AH, et al, 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published online ahead of print November 12, 2013].<i>Circulation</i>. 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),&quot; May 2001. Available at <a href=\"http://www.nhlbi.nih.gov/guidelines/cholesterol\" target=\"_blank\">http://www.nhlbi.nih.gov/guidelines/cholesterol</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tonstad S, Knudtzon J, Sivertsen M, et al, &ldquo;Efficacy and Safety of Cholestyramine Therapy in Peripubertal and Prepubertal Children With Familial Hypercholesterolemia,&rdquo; <i>J Pediatr</i>, 1996, 129(1):42-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cholestyramine-resin-pediatric-drug-information/abstract-text/8757561/pubmed\" target=\"_blank\" id=\"8757561\">8757561</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    White CM, Kalus JS, Caron MF, et al, &quot;Cholestyramine Ointment Used on an Infant for Severe Buttocks Rash Resistant to Standard Therapeutic Modalities,&quot; <i>J Pharm Technol</i>, 2003, 19:11-3.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Williams KD and Williams L, &quot;Diaper Rash Relief, Common Sense Remedies and Treatment,&quot; <i>Int J Pharm Compound</i>, 2011, 15(6):464-9.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13152 Version 127.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F150870\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F150871\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1051702\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F20234285\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1051696\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F150849\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F150834\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1051705\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F150865\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1051704\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F150895\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F150856\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F150838\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25855404\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299034\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F150843\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F150866\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F150846\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F150859\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1051701\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F150837\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F150855\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F150858\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F150861\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13152|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cholestyramine-resin-drug-information\" class=\"drug drug_general\">Cholestyramine resin: Drug information</a></li><li><a href=\"topic.htm?path=cholestyramine-resin-patient-drug-information\" class=\"drug drug_patient\">Cholestyramine resin: Patient drug information</a></li></ul></div></div>","javascript":null}